KHPG(SZ:002773)2022-12-04 09:30Sales Performance - In Q1 2020, the revenue from biological products decreased by approximately 35% compared to the same period last year, while traditional Chinese medicine revenue fell by about 11.1%, and chemical drugs increased by approximately 8.8% [4] - The decline in revenue for the drug Conbercept was attributed to the COVID-19 pandemic, which led to a significant drop in patient visits due to the closure of ophthalmology clinics [4] - As of April 2020, the injection numbers for Conbercept increased by over 100% compared to March [4] Clinical Trials - The global Phase III clinical trials for Conbercept are being conducted in over 30 countries with 300 clinical trial centers, aiming to recruit 1,140 subjects for each of the two independent trials [5] - The trials are designed to evaluate the efficacy and safety of Conbercept for treating neovascular age-related macular degeneration [5] - Despite the pandemic, the clinical trials are proceeding as planned, with measures in place to ensure participant safety [6] Research and Development - In 2019, R&D investment accounted for 24.18% of revenue, with an expected decrease to around 15% in 2020, but anticipated to maintain or grow in the coming years [7] - The company is focusing on enhancing its product pipeline in core therapeutic areas such as ophthalmology and neurology, with ongoing research for various drugs [7][8] - The company has introduced new drugs for conditions like Alzheimer's disease and is advancing multiple products through clinical trials [8] Market Strategy - The company has adjusted its sales strategy in response to new industry policies, achieving a recovery in traditional Chinese medicine sales by the end of 2019 [9] - The company’s products, including Conbercept, have demonstrated significant economic advantages and efficacy, positioning them well in the market [11] - The company is committed to improving treatment access in grassroots hospitals through educational initiatives and training programs for healthcare professionals [11]